Marshall Wace, LLP I Teos Therapeutics, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$5.04 - $10.2 $2.48 Million - $5.02 Million	492,091 Added 411.59%	611,649 $6.1 Million
Q1 2025 May 15, 2025	BUY	$5.97 - $8.15 $713,761 - $974,397	119,558 New	119,558 $713,000
Q2 2023 Aug 14, 2023	SELL	$12.93 - $18.05 $253,169 - $353,419	-19,580 Reduced 35.59%	35,429 $469,000
Q1 2023 May 15, 2023	BUY	$13.02 - $22.62 $716,217 - $1.24 Million	55,009 New	55,009 $748,000
Q2 2022 Aug 15, 2022	SELL	$16.57 - $35.1 $2.57 Million - $5.45 Million	-155,373 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$31.92 - $47.45 $1.96 Million - $2.92 Million	-61,449 Reduced 28.34%	155,373 $5 Million
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $4.2 Million - $7.67 Million	160,265 Added 283.37%	216,822 $10.1 Million
Q3 2021 Nov 15, 2021	SELL	$23.91 - $29.58 $2.07 Million - $2.55 Million	-86,372 Reduced 60.43%	56,557 $1.53 Million
Q2 2021 Aug 13, 2021	BUY	$17.9 - $36.1 $2.56 Million - $5.16 Million	142,929 New	142,929 $3.67 Million

14.1M

511K

151K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $361M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.